🧾 What This Document Is

This is a Definitive Proxy Statement (DEF 14A) for Assertio Holdings, Inc. (ASRT). It’s like the official invitation and agenda for the company's Annual Meeting of Stockholders, which will be held virtually on May 5, 2026, at 11:30 a.m. Central Time.

👉 Why it matters: Before the meeting, the company must give shareholders all the info they need to vote on important issues. This document details those issues, introduces the people running the company, explains how much the bosses get paid, and asks for your formal approval on specific plans.

🏢 What The Company Does

In simple terms, Assertio is a specialty pharmaceutical company. They don't discover new drugs; they focus on commercializing and marketing existing medicines, particularly in areas like pain and inflammation.

👉 Their key product mentioned throughout is Rolvedon (a drug for chemotherapy-induced neutropenia), which was a major driver of their 2025 sales. The company is working to streamline its operations after integrating various product lines.

🗳️ What You're Voting On

Stockholders will vote on four main proposals. The Board recommends voting "FOR" all of them.

Proposal 1: Elect Directors You're voting to elect six people to the Board to serve until the next annual meeting. This includes the current Chairman, the new CEO, and other experts in finance, law, and pharma.
Proposal 2: Approve the Incentive Plan Amendment This asks to increase the number of shares available for grants under the company's employee stock plan. More shares in the plan help attract and retain talent by offering stock-based compensation.
Proposal 3: Advisory Vote on Executive Compensation ("Say-on-Pay") This is your chance to approve, on a non-binding basis, the pay package for the top executives, including the CEO. It's a way for shareholders to voice approval or concern.
Proposal 4: Ratify the Auditor This votes to approve Grant Thornton LLP as the company's independent accounting firm for 2026. It's a routine but important check on financial oversight.

👥 Meet the Leadership & Board

The document provides detailed bios for the six director nominees and the four executive officers.

Board Nominees: Includes Heather L. Mason (Chairman, retired Abbott exec), Mark L. Reisenauer (the new CEO since Oct. 2025), and others with deep finance, legal, and pharmaceutical industry experience.
Executive Team: Led by CEO Mark Reisenauer, CFO Ajay Patel, President/COO Paul Schwichtenberg, and General Counsel Sam Schlessinger.

👉 The Board has three key committees (Audit, Compensation, Nominating & Governance), all staffed with independent directors as required by stock exchange rules.

💰 Executive Compensation Details

This is a major focus. The "Summary Compensation Table" shows what the top executives earned in 2025.

New CEO, Mark Reisenauer: His 2025 total compensation was ~$1.45 million, mostly from a new hire equity package. His 2026 target bonus is 85% of his $800,000 salary.
Former CEO, Brendan O'Grady: He left in October 2025 and received ~$1.88 million in 2025, including severance and forfeited equity.
Other Executives: CFO Patel and President Schwichtenberg earned ~$921k and ~$946k respectively. Their pay includes a mix of salary, annual cash bonuses, and stock awards.

👉 How bonuses work: The 2025 cash bonus was based 50% on financial goals (Revenue & Adjusted EBITDA) and 50% on business goals (like integration and compliance). The company hit its financial targets, resulting in 100% achievement for that portion.

📊 Financial Snapshot & Ownership

2025 Performance: Full-year product sales were $117.1 million, with Rolvedon contributing $68.2 million. The company reported a GAAP net loss of $30.4 million but a positive non-GAAP Adjusted EBITDA of $22.7 million.
Who Owns the Company? As of March 9, 2026, there were 6.4 million shares outstanding. The largest shareholder listed is Nantahala Capital Management, with about 9.3% of shares. All directors and officers together own about 5.7%.

🔮 What's Next & Key Moves

The company highlighted its 2025 accomplishments and direction:

Leadership Change: Appointed Mark Reisenauer as new CEO in October 2025, bringing extensive commercial launch experience.
Strategic Focus: Advancing integration efforts to consolidate operations and align products under one commercial entity for efficiency.
Risk Reduction: Settled legacy legal matters (DOJ, class actions) and simplified its corporate structure to remove opioid litigation exposure.
Supply Security: Amended its manufacturing agreement for Rolvedon to fix prices for the remainder of the license term.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

New CEO with strong commercial background in specialty pharma.
Key product Rolvedon is a significant revenue driver.
Proactive steps to settle costly legal issues and secure supply chain.
Strong board with relevant industry expertise.

⚠️ Risks:

Recent financial performance shows a GAAP net loss, indicating challenges in overall profitability.
The company is in a transition period, integrating operations, which carries execution risk.
As a specialty pharma company, it is heavily dependent on the performance of a limited number of products like Rolvedon.
Future growth depends on successful commercial execution and pipeline development.

🧠 The Analogy

Think of Assertio's annual meeting like a "State of the Union" for shareholders, combined with a boardroom hiring session. Management reports on the past year's wins and losses (the "state"), presents a strategic plan for moving forward, and then asks the owners (shareholders) to vote on whether to re-hire the board of directors and approve the executive compensation package they've designed.

🧩 Final Takeaway

This proxy statement is about governance and transition. Shareholders are being asked to approve the new leadership team (Board and CEO) and their pay, while also ratifying the stewardship of the company's finances. The underlying story is a company working to streamline operations, reduce legal risks, and drive growth from its key product under new executive command.

Assertio Holdings, Inc. — DEF 14A Filing